LifeMD, Inc. (NASDAQ:LFMD) Receives $9.25 Average Target Price from Analysts

by · The Markets Daily

LifeMD, Inc. (NASDAQ:LFMD – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the nine research firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $9.25.

LFMD has been the topic of a number of analyst reports. Wall Street Zen cut LifeMD from a “hold” rating to a “sell” rating in a research report on Saturday, November 22nd. KeyCorp lowered their target price on shares of LifeMD from $12.00 to $8.00 and set an “overweight” rating on the stock in a report on Wednesday, November 19th. Weiss Ratings reiterated a “sell (e+)” rating on shares of LifeMD in a research report on Monday, December 29th. B. Riley reduced their price target on shares of LifeMD from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. Finally, BTIG Research decreased their price objective on shares of LifeMD from $18.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th.

Get Our Latest Report on LFMD

LifeMD Stock Performance

Shares of LifeMD stock opened at $3.91 on Thursday. The firm has a market cap of $188.23 million, a P/E ratio of -23.00 and a beta of 1.45. The firm’s 50-day simple moving average is $4.14 and its 200-day simple moving average is $6.86. LifeMD has a twelve month low of $3.18 and a twelve month high of $15.84.

LifeMD (NASDAQ:LFMD – Get Free Report) last announced its quarterly earnings results on Monday, November 17th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.04). The business had revenue of $60.17 million for the quarter, compared to analysts’ expectations of $62.07 million. During the same period last year, the company posted $0.09 EPS. On average, equities analysts forecast that LifeMD will post -0.56 earnings per share for the current fiscal year.

Insider Buying and Selling

In other LifeMD news, CMO Jessica Friedeman sold 15,000 shares of LifeMD stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $3.61, for a total value of $54,150.00. Following the completion of the transaction, the chief marketing officer owned 205,000 shares in the company, valued at approximately $740,050. The trade was a 6.82% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 18.40% of the stock is currently owned by company insiders.

Institutional Trading of LifeMD

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Nisa Investment Advisors LLC increased its position in LifeMD by 148.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,656 shares of the company’s stock valued at $50,000 after acquiring an additional 2,185 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in shares of LifeMD by 110.4% during the second quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company’s stock valued at $64,000 after purchasing an additional 2,452 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its stake in shares of LifeMD by 1,004.9% during the second quarter. Caitong International Asset Management Co. Ltd now owns 5,171 shares of the company’s stock valued at $70,000 after purchasing an additional 4,703 shares during the last quarter. Quarry LP acquired a new stake in shares of LifeMD in the third quarter valued at approximately $52,000. Finally, Baader Bank Aktiengesellschaft bought a new position in LifeMD in the 2nd quarter worth approximately $136,000. 35.52% of the stock is currently owned by institutional investors and hedge funds.

LifeMD Company Profile

(Get Free Report)

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.

Further Reading